Markets · 1 sources covering this

Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal

Nuvalent's shares surged 39% to $123 after GlaxoSmithKline agreed to acquire the cancer drug developer for $10.6 billion, enhancing its oncology portfolio.&nbsp;

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

MintLean R·2h ago
Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal
Nuvalent's shares surged 39% to $123 after GlaxoSmithKline agreed to acquire the cancer drug developer for $10.6 billion, enhancing its oncology portfolio.&nbsp;
Read at Mint →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/5798fb68454bd3db084e96173a21a2d5fbddbae3"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal"></iframe>

Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal

How 1 sources are covering this

Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal

More from Markets

Shapoorji Pallonji Group stock to be in focus on Wednesday on bagging ₹5300 crore order. Details here

Brent crude oil price falls below $90 a barrel on hopes of Iran deal

NLC India OFS oversubscribed 5.22 times on day one; govt exercises full greenshoe option

Ahead of Market: 10 things that will decide stock market action on Wednesday

Reader

Trust & legal

Across the network